@ARTICLE{
author={Davies Andrew,Merli Francesco,Mihaljevic Biljana S,Siritanaratkul Noppadol,Solal-Celigny Phillippe,Barrett Martin,Berge Claude,Bittner Beate,Boehnke Axel,McIntyre Christine,MacDonald David},
year={2014},
title={Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study},
journal={LANCET ONCOLOGY},
volume={15},
number={3},
pages={343-352},
document_type={Article},
} 

@ARTICLE{
author={Davies Andrew,Merli Francesco,Mihaljevic Biljana S,Siritanaratkul Noppadol,Solal-Celigny Philippe,Boehnke Axel,Berge Claude,McIntyre Christine,Barrett Martin,Macdonald David},
year={2013},
title={Subcutaneous Rituximab and Chemotherapy Achieves Similar Trough Levels, Safety, and Response as Intravenous Rituximab in First-Line Follicular Lymphoma: Stage 1 Results of the Phase 3 Sabrina Study},
journal={HAEMATOLOGICA},
volume={98},
number={},
pages={131-132},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Davies AJ,Merli Francesco,Mihaljevic Biljana S,Siritanaratkul Noppadol,Solal-Celigny Philippe,Boehnke Axel,Berge Claude,McIntyre Christine,Barrett M,MacDonald D},
year={2013},
title={Pharmacokinetics (PK), safety and overall response rate (ORR) achieved with subcutaneous (SC) administration of rituximab in combination with chemotherapy were comparable to those achieved with intravenous (IV) administration in patients (pts) with follicular lymphoma (FL) in the first-line setting: Stage 1 results of the phase III SABRINA study},
journal={BRITISH JOURNAL OF HAEMATOLOGY},
volume={161},
number={},
pages={7-8},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Davies Andrew J,Merli Francesco,Mihaljevic Biljana S,Siritanaratkul Noppadol,Solal-Celigny Philippe,Boehnke Axel,Berge Claude,McIntyre Christine,Barrett Martin,Macdonald David},
year={2012},
title={Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334)},
journal={BLOOD},
volume={120},
number={21},
pages={-},
document_type={Meeting Abstract},
}